SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bo Didley who wrote (50567)7/14/1999 8:27:00 PM
From: Bo Didley  Read Replies (2) of 120523
 
SCIENCE OF THE COMMON COLD * * * * * * * *

A major reason for the failure of medical science to find a cure for the common cold is the fact that the common cold can be caused by one of over 200 different viruses. This being the case, the standard medical paradigm of treating infectious ailments by vaccine has not been a viable option. It is known that the main portal of entry of the cold virus into the body is the cell lining of the nasal cavity. In the 1980's, it was discovered that the majority of the viruses responsible for the common cold all used a common entry point into the human body; the nasal cell ICAM-1 receptor. It was evident that if scientists could find a way to block the attachment of the cold viruses to the ICAM-1 receptors, a cure for the common would be at hand.

In 1995, Dr. Charles B. Hensley and Dr. R. Steven Davidson (two of Gel Tech's founders) developed the ionic free flow emulsification technology which led to their discovery of the compound, ZinulloseTM, which blocks the ability of the cold virus from binding to the ICAM-1 binding sites and from infecting the nasal cells. Subsequently, Drs. Hensley and Davidson developed ZICAMTM, a cold remedy containing ZinulloseTM designed to reduce the duration of the common cold. Subsequent double blind research demonstrated that ZICAMTM is highly effective as a treatment for the common cold, reducing the duration of the cold from 10-14 days to an average of 1.5 days (Hensley and Davidson, 1998). zicam.com

GUMM is the 60% owner of ZICAM.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News